行情

ACER

ACER

Acer医疗
NASDAQ

实时行情|Nasdaq Last Sale

3.300
-0.050
-1.49%
交易中 14:57 02/25 EST
开盘
3.300
昨收
3.350
最高
3.320
最低
3.100
成交量
10.90万
成交额
--
52周最高
5.84
52周最低
1.080
市值
4,722.38万
市盈率(TTM)
-1.5923
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
Acer Therapeutics宣布在进食条件下将ACER-001与BUPHENYL进行生物等效性试验得出的主要结果;数据显示ACER-001与BUPHENYL相比具有相似的PK分布
NEWTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and
Benzinga · 02/11 13:32
Needham Keeps a Hold Rating on Acer Therapeutics (ACER)
Needham analyst Serge Belanger maintained a Hold rating on Acer Therapeutics (ACER) today. The company's shares closed last Monday at $4.26. According to
SmarterAnalyst · 01/25 19:55
UPDATE: Acer To Receive $1M Payment To Obtain Exclusivity And A $4M Loan From Relief; If Definitive Agreement Is Executed, Acer To Receive $15M In Cash, Relief To Pay Up To $20M In Development And Commercial Costs
Under the terms of the Option Agreement, Acer will receive from Relief a $1 million non-refundable payment in return for exclusivity until June 30, 2021 to negotiate and enter into a definitive collaboration
Benzinga · 01/25 13:39
救济治疗学,宏cer治疗学签署了排他性选择权协议,以就ACER-001在世界范围内开发和商业化治疗尿素循环系统疾病和枫糖浆尿病进行谈判,达成合作和许可协议;宏cer将获得$ 1M的付款以获得排他性和$ 400万的贷款
RELIEF THERAPEUTICS Holding AG (OTC: RLFTF) and Acer Therapeutics Inc.
Benzinga · 01/25 10:45
Acer Therapeutics宣布全面注册ACER-001的尿素循环系统紊乱生物等效性试验
Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle Disorders NEWTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical
Benzinga · 2020/12/22 13:33
Acer Therapeutics Q2 EPS $(0.56) Up From $(1.09) YoY
Acer Therapeutics (NASDAQ:ACER) reported quarterly losses of $(0.56) per share. This is a 48.62 percent increase over losses of $(1.09) per share from the same period last year.
Benzinga · 2020/08/13 20:04
电竞显示成电视行业第二战场
家电消费网 · 2020/08/11 15:51
Insider Buys Acer Therapeutics's Shares
Shares of Acer Therapeutics Inc (NASDAQ:ACER) moved higher by 7.5% from the previous closing price. A Form 4 filing filed with the SEC on Tuesday, July 28 showed that President & CEO Schelling Chris bought 142,857 shares at an average price of $3.50. The trans
Benzinga · 2020/07/28 15:09
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解ACER最新的财务预测,通过ACER每股收益,每股净资产,每股现金流等数据分析Acer医疗近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测ACER价格均价为10.00,最高价位10.00,最低价为10.00。
EPS
机构持股
总机构数: 64
机构持股: 279.61万
持股比例: 19.54%
总股本: 1,431.02万
类型机构数股数
增持
2
5.92万
建仓
13
57.45万
减持
8
2.31万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-1.86%
制药与医学研究
-0.99%
高管信息
Chairman/Independent Director
Stephen Aselage
President/Chief Executive Officer/Director
Christopher Schelling
Chief Financial Officer
Harry Palmin
Vice President - Finance/Controller
Jason Kneeland
Vice President
Stacey Bain
Vice President
Terrie Kellmeyer
Vice President
John Klopp
Vice President
Kristin Mulready
Vice President
Matt Seibt
Other
William Andrews
Director of Marketing
Kim Tharaldsen
Independent Director
Jason Amello
Independent Director
Hubert Birner
Independent Director
John Dunn
Independent Director
Michelle Griffin
Independent Director
Luc Marengere
  • 分红
  • 拆股
  • 内部人交易
暂无数据
ACER 简况
Acer Therapeutics Inc(原名:Opexa Therapeutics Inc)是一家制药公司。该公司从事获、开发并试图商业化用于患有严重罕见疾病且有严重未满足医疗需求的患者的疗法。其临床后期产品包括Edsivo(celiprolol)和ACER-001。该公司在美国正在开发治疗血管性埃勒斯-当洛斯综合征(vEDS)的产品Edsivo。其正在开发ACER-001,这是一种用于治疗枫糖尿症(MSUD)的药物治疗选择。ACER-001是使用微囊化工艺开发的苯基丁酸钠(NaPB)的速释制剂。该公司也正在开发治疗尿素循环障碍的ACER-001。

微牛提供Acer Therapeutics Inc(NASDAQ-ACER)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ACER股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ACER股票基本功能。